Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betamethasone in mothers with PROM at 34 to 36 weeks
IRCT20221010056141N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of betamethasone in Rupture of amniotic membranes (PROM) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Neonatal respiratory distress score, Need for surfactant and 4 more. Started Jan 2023; status: completed.
02
Drugs
betamethasone
03
Conditions
Rupture of amniotic membranes (PROM)
Beyond the preview
Go deeper on IRCT20221010056141N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221010056141N1.